Currently, there are confl icting data on the impact of recipient/donor ABO-incompatibility upon development of complications and eff ectiveness of treatment in allogeneic hematopoietic stem cell transplantation (allo-HSCT). Th e aim of our study was to specify the role of ABO-and Rh-incompatibility in allo-HSCT for a well-characterized cohort of patients.
Introduction
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is eff ective method of treatment for malignancies, some solid tumors and hereditary diseases in children and adults [1] . Th e main success factors are dependent on the underlying disease status at the time of therapy initiation, and the level of HLA-match between recipient and donor of hematopoietic stem cells which is a key factor to increase the chance for engraft ment, and to reduce development of acute and chronic graft -versus-host disease (GvHD) [2] .
Since the beginning of allo-HSCT implementation as a treatment method from the middle of the XX century, there is a great progress in accessibility and safety of this treatment approach. However, ABO-and Rhesus-incompatibility between patient and donor in allo-HSCT are shown in 30-50% of cases, thus leading to additional complications and erythrocyte recovery delay [3, 4] . Th e presence of ABO-incompatibility requires higher level of immunological security measures while providing replacement transfusion therapy: compliance with ABO-compatibility rules, depending on the level of posttransplant chimerism; X-or γ-irradiation of erythrocyte and platelet-containing blood products before transfusion, leukofi ltration technology [5] .
Th ere are three ABO-incompatibility types -minor (20-25% of all cases), major (20-25%) and bidirectional (5%) ( Table 1 ) [6] .
ABO-incompatibility may predispose for some severe complications, such as acute and delayed hemolysis, pure red cell aplasia (PRCA) [7] , GvHD [8] , graft failure [9] , autoimmune hemolytic anemia [10] , which negatively aff ect the eff ectiveness of HSCT by increasing mortality [11] . At the same time, there are studies which yield confl icting results and do not reveal distinct impact of ABO mismatch upon the treatment outcomes [8, 12, 13] . Data ambivalence of ABO-and Rhesus-incompatibility impact in allo-HSCT, determined a rationale of a large cohort study, which would allow of creating more homogeneous comparison groups by the main parameters, and, therefore, increase the signifi cance of results. Th e aim of our study was to specify the role of ABO-incompatibility in allo-HSCT for a well-characterized cohort of patients.
Patients and methods
From 1999 to 2015, 1132 patients with malignancies and hereditary diseases undergone 1482 allo-HSCT at the R. Gorbacheva Memorial Institute for Children Oncology, Patients with acute myeloid leukemia (n=568), acute lymphoblastic leukemia (n=475), chronic myeloid leukemia (n=94), myelodysplastic syndrome (n=76), severe aplastic anemia (n=57) represented the dominant clinical group. Over recent years, an increased allo-HSCT activity has been registered for orphan diseases (n=49) and solid tumors in children (n=9).
Th e choice of conditioning regimen was determined by diagnosis, disease status and patient somatic state. Myeloablative conditioning regimen (MAC) was used in 431 patients (29.5%), non-myeloablative regimens (RIC), were applied in 1030 cases (70.5%). Busulfan + cyclophosphamide drug combination (n=301) was the most frequently used protocol (69.8% of total MAC-treated group). RIC regimens, i.e., busulfan+ fl udarabine, or melphalan+ fl udarabine were used, respectively, in 515 (50%) and 21% (n=217). Evaluation engraft ment and staging of posttransplant complications were made according to standard defi nitions and classifi cations [14] [15] [16] [17] , and EBMT 2012 Recommendations. Th e fi rst detection of donor RBC in two or more consecutive peripheral blood tests by serological methods was considered to be the beginning of donor chimerism [18] .
Standard laboratory techniques for ABO, Rh (D, C, c, E, e, K, C w ) and Cellano (Kell) evaluation were used: cross-method with monoclonal antibodies and micro-typing system (IDcard, Bio Rad). Direct antiglobulin test was made by standard gel method (ID Liss Coombs, DC-Screening I, Bio Rad Laboratories).
In order to reduce the risk of immune transfusion reactions in case of ABO-incompatibility, graft manipulation technologies were used: in case of major ABO-incompatibility, removal of incompatible donor erythrocytes (sedimentation with 6% hydroxyethyl starch); in case of minor incompatibility, donor plasma was removed by centrifugation procedure; in case of bidirectional mismatch, a combination of the methods was used.
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If necessary, blood transfusion therapy was carried out according to ABO-status and general recommendations [6] .
Statistical analysis was performed using IBM SPSS Statistics version 13.0 by the rules and international recommendations for processing and providing the results of HSCT [19] and include following statistical methods: descriptive statistics for quantitative variables, parametric statistics, description of nominal variables (ABO-incompatibility impact assessment on the development of GvHD); overall survival (OS) analysis was performed by Kaplan-Mayer method using logrank test. To reveal the factors associated with engraft ment terms, a logarithmic utility function (logworth) was used. Th e role of various factors infl uencing posttransplant period and chimerism development was assessed by multivariate analysis (Cox regression). Th e diff erence between individual indicators was considered statistically signifi cant at p<0.05.
Results

Impact of ABO blood groups and Rhesus factor on the allo-HSCT effectiveness
In the present study, comprehensive analysis on the impact of ABO-and Rhesus-incompatibility on allo-HSCT effi ciency and risk of complications was performed. Patient's ABO blood group, as an independent parameter, did not aff ect 1-year OS in patients with malignant diseases in allo-HSCT Rhesus system antigens have a much lower degree of immunogenicity compared to potential eff ects of ABO system, but it can contribute to allo-sensibilisation and promotion of hemolytic complications, thereby reducing the effi ciency of allo-HSCT, which was confi rmed in this study. When comparing pre-transplant RBC phenotypes in the patients with malignancies (n=1175), the following combinations have been found to aff ect the one-year OS ( Fig. 2 ): -DCCee (n=197) vs ddccee (n=157), 65% (mean, 9.5 months; HR 0.283; 95% CI 8.945-10.056) and 50% (median, 11.4 months; HR 0.348; 95% CI 7.706-9.069), respectively, p=0.006; -Dccee (n=450) vs ddccee (n=157), 63% (mean -9 months, HR 0.198; 95% CI 8.672-9.45) and 50%, respectively, p=0.025.
Studying clinical eff ects and outcomes depending on the Rh antigen status of the donor (n=998) confi rm the assumption of a more pronounced negative eff ects of homozygous and 2,00 4,00 6,00 8,00 10,00 12,00 D-negative Rh phenotypes upon overall patient survival ( Fig. 3 The impact of ABO-mismatches on OS and the risk of GvHD development in allo-HSCT
In our study, ABO-incompatibility (n=1428) was documented in 54.6% of allo-HSCT cases (n=780), with major or minor mismatch shown, respectively in 37.8% (n=295), and 45.4% of the cases (n=354); and bidirectional incompatibility having been registered in 16.8% of the cohort (n=131), which is slightly more frequent compared to the worldwide data [4] , due to specifi c variability of the gene polymorphisms in the multinational population of Russian Federation, and a signifi cant number of graft s from the foreign unrelated donors used at our HSCT Center.
Th e authors opinion and literature data on the impact of ABO-incompatibility on OS are contradictory since most of them did not prove a negative infl uence upon HSCT outcome. However, the 10-year experience of French BMT group (n=1108) indicate to a negative impact of minor ABO-incompatibility in allo-HSCT patients treated with RIC combination with fl udarabine and low-dose total body irradiation or fl udarabine and busulfan with rabbit ATG, along with absence of remission, and inclusion of ATG>10mg/kg into the GvHD prophylaxys schemes [20] .
According to our data, minor ABO-incompatibility in patients with leukemia in remission (n=600) was associated with reduced D+100 OS rates when compared with ABO-compatible allo-HSCT, p=0.05 (Fig. 4 Further analysis was performed according to the type of ABO-incompatibility in combination with conditioning regimens, GvHD prophylaxis, taking into account diff erent degree of myeloablation, mechanisms of immunosuppression and possible risk potentiation for immune complications.
A combination of MAC and major ABO-incompatibility in patients with leukemia in remission (n=215) was found to be associated with a decreased OS at 100-days aft er allo-HSCT, if compared with ABO-compatible allo-HSCT, CTT JOURNAL | VOLUME 7 | NUMBER 4 | DECEMBER 2018
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p=0.025 (Fig. 5) 
Discussion
A high risk for ABO-incompatibility is an additional factor potentiating immunological reactivity, thus increasing risk of GvHD and possible hemolytic complications remains controversial. A number of publications noted higher frequency of acute GvHD grade III-IV in the case of major and minor ABO-incompatibility [21] . On the other hand, a group of scientists from Seattle presented data from the large US National Bone Marrow Donor Program showing no signifi cant diff erence in the development of acute GvHD depending on the ABO-incompatibility type [22] .
Results of our study indicate that the type of ABO-incompatibility: major (n=123), minor (n=167) or bidirectional (n=61) did not increase either severity, or incidence of acute GvHD (grade I-IV) in patients with leukemia transplanted in remission (n=626), compared to ABO-compatible HSCT (n=275), p=0.85. Acute GvHD developed in ABO-compatible HSCT in 52% of cases (n=143), in major ABO-incompatibility, 48.8% (n=60), in minor ABO-mismatch, 50.9% (n=85), in bidirectional mismatch, 55.7% (n=34), respectively.
Likewise, the type of ABO-incompatibility: major (n=123), minor (n=167), bidirectional (n=61); did not increase the risk of chronic GvHD in patients with leukemia treated in remission (n=626) compared to ABO-compatible HSCT (n=275), p=0.21. Chronic GvHD developed in ABO-compatible HSCT in 26.5% of cases (n=73); in major ABO-incompatibility, 24.4% of cases (n=30); in minor, 24% of cases (n=40); in bidirectional, 37.7% (n=23), respectively.
The impact of ABO-incompatibility on engraftment
According to the results of our study, in general cohort of patients with allo-HSCT, the leukocyte recovery >1.0x109/l was observed on day 18 (mean ± standard deviation -20±10.4); neutrophil recovery >0.5x10 9 /l -on day 17 (20.5±13.6); platelet recovery >20x10 9 /l -on day 14 (21±17.8); platelet recovery >50x10 9 /l -on day 16 (23.2±15). Th e most significant factors which determined time of engraft ment were as follows: HLA-match (logworth, 15.1), graft source (logworth, 7.05), type of allo-HSCT (logworth 6.4), conditioning regimen (logworth, 4.05). Th e factors which increased the engraft ment time were as follows: 9/10 HLA-match, MAC regimen, bone marrow as a source of transplant. In turn, ABO-and Rhesus-incompatibility had a much smaller impact on neutrophils and platelets engraft ment timeline: ABO-incompatibility (logworth of 0.87), blood group of the donor (logworth, 0.34), patient's erythrocyte phenotype (logworth, 0.33), donor's Rhesus factor (logworth, 0.27), donor's erythrocyte phenotype (logworth, 0.001).
However, as exemplifi ed by 240 recipients of allo-HSCT, the diff erences in recovery time of erythrocyte counts on D+50 proved to be dependent on ABO-incompatibility, i.e., the patients from ABO-compatible donor/patient pairs achieved RBC recovery in 23.8% of cases, and those with ABO-incompatibility, in 10% (p=0.01).
Th e results of this study suggest that the 100% donor chimerism for ABO blood groups was reached in 159 of 240 patients (17 to 229 days, a median of 84 days). In 81 patients, the results could not be assessed due to their death in early posttransplant period (n=50); inability to identify diff erences, due to identity for ABO-, Rhesus-system (D, C, c, E, e) and Kell markers (n=7); lack of laboratory data due to incomplete patient's data obtained posttransplant (n=24). Table 3 . Development of immune complications in allo-HSCT depending on the ABO-incompatibility type Primary diagnosis (p=0.87), disease status (p=0.69), allo-HSCT type (p=0.26), graft source (p=0.28), degree of HLA match (p=0.62) and conditioning regimens (p=0.39) did not have a negative impact on blood group conversion terms. ABO-incompatibility was the only identifi ed factor increasing chimerism time development (p=0.0001). For ABO-compatible allo-HSCT with Rh incompatibility (n=52), the time to achieve 100% chimerism was 95±44 days (31-226 days, HR 6,106; 95% CI 82.9-107.4), with major ABO-incompatibility (n=29) -109±51 days (27-229 days, HR 9.642; 95% CI 89.9-129.4), with minor (n=57) -67±22 days (17-109 days, HR 3,032; 95% CI 61-73,1), with bidirectional mismatches (n=21) -72±16 days (48-117 days, HR 3,515; 95% CI 65,3-80).
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Negative eff ect of ABO-incompatibility type on erythroid time recovery, is refl ected in posttransplant transfusion therapy intensiveness (p=0,003). Th e average number of transfusions of blood components was 25 units in major ABO-incompatibility (p=0.001); 16.5, in minor mismatch (p=0.006); 13.6, in bidirectional (p=0.005); 15.1, in ABO-compatible allo-HSCT (p=0.001), respectively.
HSCT complications associated with ABO-incompatibility
Additional attention is paid to the development of specifi c complications associated with ABO-incompatibility. Clinical manifestations in this case may be due to localization of ABO system antigens, which are represented not only on erythrocytes, but also on other cells and tissues: platelets, lymphocytes, endothelium of blood vessels and organs (kidneys, liver, heart) circulating in plasma [23] .
According to our data, the risk of immune complications in allo-HCT (n=1158) is 2.8% (n=33) versus 4.1% in the presence of ABO-incompatibility (n=638, p=0.02), as seen from Table 3 . A low number of cases and mortality (n=3) may indicate adequate prevention, timely and eff ective treatment.
Design of OS predictive models in allo-HSCT
One of the main objectives in multivariate analysis was to identify factors and their combinations that aff ect OS in allo-HSCT, and to create a mathematical model for predicting the probability of potential complications, which will allow for timely prophylaxis and treatment. Th e study was based on Cox regression with preliminary exploratory analysis for patients with malignant diseases, which was performed as a Kaplan-Meier test for nominal variables-factors aff ecting the outcome of treatment [24] . As a result of the analysis, the following predictors aff ecting OS were identi- fi ed: degree of HLA-match, presence of acute GvHD, major ABO-incompatibility, allo-HSCT type, status of the underlying disease, and use of ATG for GvHD prophylaxis (Fig. 6) .
Our valid predictive model of 100-day OS may serve such an example, which included patients with leukaemia (n=140) from 9/10 HLA-matched related and unrelated donor, in case of engraft ment up to D+31 (Fig. 7) . 
Overall survival profiles
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Conclusion
Th e data presented in this study suggest that ABO-incompatibility may be a negative factor reducing eff ectiveness of treatment in allo-HSCT, especially in the early posttransplantation period and during the fi rst year posttransplant. Adverse eff ects of ABO-incompatibility are realized through allosensitization, increasing the frequency of hemolytic complications and delaying erythroid recovery.
It seems that the main tool for minimizing the ABO-incompatibility consequences is the donor graft preparation based on ABO-incompatibility type, which allows achieving low frequency and severity of possible hemolytic complications.
Th e next factor of important value is the replacement transfusion therapy, which should be based on red blood cells chimerism level and comply with the principles to use the most leukocyte depleted blood components, which can improve the effi ciency of blood transfusions and reduce the risk of posttransfusion reactions and complications.
Th us, when choosing an allogeneic bone marrow donor, giving priority to a higher degree of HLA-match and CMV-status in "recipient-donor" pair, it is also optimal to choose, if possible, an ABO-and Rhesus compatible donor.
Роль АВО-и резус-несовместимости при аллогенной трансплантации гемопоэтических стволовых клеток Резюме В настоящее время существуют противоречивые данные о негативном влиянии АВО-несовместимо-сти на вероятность развития осложнений и эффек-тивность лечения при аллогенной трансплантации гемопоэтических стволовых клеток (алло-ТГСК). Целью работы было изучение роли антигенов АВО-несовместимости при алло-ТГСК.
